Navigation Links
AcelRx Pharmaceuticals to Present at Two Healthcare Investor Conferences in the Second Half of September
Date:9/15/2011

REDWOOD CITY, Calif., Sept. 15, 2011 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and Chief Executive Officer, will present at two separate investor conferences in New York City over the coming weeks as follows:

UBS Global Life Sciences Conference

Date:  Tuesday, September 20th at 7:30 AM EST

Location:  Grand Hyatt New York

Webcast link:  http://cc.talkpoint.com/ubsx001/091911a_im/?entity=109_C624HWQ

The Sixth Annual JMP Securities Healthcare Conference

Date:  Wednesday, September 28th at 11:00 AM EST

Location:  The St. Regis New York

Webcast link:  http://wsw.com/webcast/jmp14/acrx/

Both presentations will be webcast live and can be accessed through the links above.  For those not available to listen to the live broadcast, the presentations will be archived and available through http://www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.

Based in Redwood City, CA, AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, the ARX-01 Sufentanil NanoTab PCA System, which is in preparation for Phase 3 clinical development, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps. AcelRx has two additional product candidates which have completed Phase 2 clinical development: ARX-02 for the treatment of cancer breakthrough pain, and ARX-03 for providing mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. A fourth product candidate, ARX-04, is a sufentanil product for the treatment of moderate-to-severe acute pain that is expected to enter Phase 2 clinical development in the second half of 2011 under a grant from the US Army Medical Research and Material Command.


'/>"/>
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AcelRx Pharmaceuticals to Present at the Rodman & Renshaw Global Investment Conference
2. AcelRx Pharmaceuticals to Present at the Canaccord Genuity Growth Conference
3. AcelRx Pharmaceuticals Reports First Quarter 2011 Financial Results
4. AcelRx European Patent Covering its NanoTab® Sublingual Delivery Technology for Acute and Breakthrough Pain Pipeline Products Emerges From Opposition Period
5. AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference
6. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
7. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
8. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
9. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
10. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
11. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017 The Global Therapy ... and access to partnering deals and agreements entered into ... in partnering deals - Top deals by value - ... development, technology type The report provides understanding and ... by the world,s leading healthcare companies. The report ...
(Date:1/19/2017)... Report Details ... Alzheimer,s Disease Therapeutics and ... our new study reveals trends, R&D progress, and predicted ... the Alzheimer,s disease therapeutics and diagnostics market. Our new ... - How is the Alzheimer,s disease therapeutics and diagnostics ...
(Date:1/19/2017)... 2017  Stealth BioTherapeutics Inc. ( Stealth ), a ... today announced new additions to its senior leadership team: ... Officer, and Daniel Geffken as interim Chief ... Carr , Pharm.D. has been promoted to Chief Clinical ... welcome Doug and Daniel to our management team, as ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... Bionic Sports Nutrition LLC, ... of life, announced it had a successful January ECRM Trade Show in Hilton Head, ... United States, which allows it to provide its products to all clients at reasonable ...
(Date:1/20/2017)... ... January 20, 2017 , ... "TransFlare 4K Mystique comes with 44 colorful mysterious ... X," said Christina Austin - CEO of Pixel Film Studios. , TransFlare 4K ... 4K Mystique lens flare and light leak transitions have a very high-dynamic range for ...
(Date:1/20/2017)... ... 20, 2017 , ... “I Forgive You”: a fine examination of how God handles sin, ... creation of published author, Stephen Miller, who, for over ten long years has been waiting ... Born in Trinidad and Tobago, he has been serving the Lord for over twenty years, ...
(Date:1/20/2017)... ... 2017 , ... “The Land of More and More”: a brilliant story ... and shares the simple and achievable answer. “The Land of More and More” is ... Missionary Church in Angola, Indiana where he works with the children’s ministry department. ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... expansion and facility enhancement of their 503A compounding pharmacy located in Ocala, Florida. ... demand of physicians and patients throughout the United States for high-quality human ...
Breaking Medicine News(10 mins):